pipeline-tablet.jpg

R&D Pipeline

FibroGen is dedicated to creating innovative, first-in-class medicines for the treatment of chronic and life-threatening or debilitating conditions such as anemia in chronic kidney disease (CKD), anemia in myelodysplastic syndromes (MDS) and chemotherapy induced anemia (CIA), locally advanced pancreatic cancer, Duchenne muscular dystrophy (DMD), and idiopathic pulmonary fibrosis (IPF). The products we develop represent more than isolated opportunities or single indications — we see our products as representing broader platforms that enable us to continue to investigate discrete pathways and mediators that are central to multiple diseases.

HIF Platform

Preclinical

Phase 1

Phase 2

Phase 3

Approved

United States

ROXADUSTAT (HIF-PHI) ANEMIA OF CKD

Phase 3

China

Approved

Europe

Phase 3

Japan

Approved

1

FDA issued a complete response letter on 8/10/21

1

ROXADUSTAT (HIF-PHI) ANEMIA IN MDS

 

United States

 

China

Phase 3

Phase 3

United States

Phase 2

ROXADUSTAT (HIF-PHI) ANEMIA IN CIA

Fibrotic Disease Platform

Preclinical

Phase 1

Phase 2

Approved

Phase 3

Phase 3

Locally Advanced Pancreatic Cancer

Idiopathic Pulmonary Fibrosis

Duchenne Muscular Dystrophy

PAMREVLUMAB
(ANTI-CTGF ANTIBODY)

Phase 3

Phase 3

Phase 3

PARTNERED
WHOLLY-OWNED
roxadustat.jpg

Roxadustat

Roxadustat, an oral medicine, is the first in a new class of medicines, HIF-PH inhibitors that promote erythropoiesis, or red blood cell production, through increased endogenous production of erythropoietin; improved iron absorption and mobilization; and downregulation of hepcidin.

Pamrevlumab

Pamrevlumab, our proprietary fully human antibody, represents a potential treatment for a broad array of fibrotic and proliferative disorders that affect organ systems throughout the body.

pipeline-blurb-img.jpg